Amarin analyst commentary at H.C. WainwrightAmarin price target raised to $51 from $31 at H.C. Wainwright. H.C. Wainwright analyst Andrew Fein raised his price target for Amarin to $51 from $31 and reiterates a Buy rating on the shares. The stock in premarket trading is down 3%, or 55c, to $20.50. The detailed data presentation of the Reduce-IT trial of Vascepa at this year's American Heart Association conference in conjunction with the publication in the New English Journal of Medicine provided much anticipated color on Vascepa's clinical benefits and commercial potential, Fein tells investors in a research note. He believes that beyond the topline of 25% reduction of MACE score, the "robustness of the data is highlighted by the consistency across pre-specified analyses." The trial data may be viewed as "unprecedented" and "paradigm-changing" in the context of minimal or modest benefits historically achieved by various therapies on top of statins, says the analyst.Read more at: https://thefly.com/landingPage...(Source theFly) * This stock has been on our trading list for a while now. Will continue to look for trades in this name. * $AMRN, Amarin Corporation plc / H1 Disclosure: I may trade in the ticker symbols mentioned, both long or short. My articles represent my personal opinion and analysis and should not be taken as investment advice. Readers should do their own research before making decisions to buy or sell securities. Trading and investing include risks, including loss of principal. If you liked this article, please click the LIKE (thumbs up) button. Feel free to leave any comments, question, or opinions. Follow us and check back occasionally for additional articles or posts.